Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - amitriptyline hydrochloride, quantity: 50 mg - tablet - excipient ingredients: lactose monohydrate; microcrystalline cellulose; maize starch; croscarmellose sodium; colloidal anhydrous silica; purified talc; magnesium stearate; macrogol 6000; hypromellose; titanium dioxide; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350 - for the treatment of major depression. entrip 50mg tablets are indicated only for the maintenance treatment of major depression (see precautions). nocturnal enuresis where organic pathology has been excluded.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - paroxetine hydrochloride, quantity: 22.21 mg (equivalent: paroxetine, qty 20 mg) - tablet, film coated - excipient ingredients: calcium hydrogen phosphate; sodium starch glycollate; colloidal anhydrous silica; magnesium stearate; purified talc; titanium dioxide; methacrylic acid copolymer - major depression and prevention of relapse of depressive symptoms. obsessive compulsive disorder (ocd) and prevention of relapse of ocd. panic disorder and prevention of relapse of panic disorder. social anxiety disorder/social phobia.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - paroxetine hydrochloride, quantity: 22.22 mg (equivalent: paroxetine, qty 20 mg) - tablet, film coated - excipient ingredients: sodium starch glycollate; magnesium stearate; microcrystalline cellulose; mannitol; basic butylated methacrylate copolymer; titanium dioxide; purified talc; polyvinyl alcohol; sodium lauryl sulfate; glyceryl monostearate - treatment of major depression and for the prevention of relapse of depressive symptoms; treatment of obsessive compulsive disorder and for the prevention of relapse of ocd; treatment of panic disorder and for the prevention of relapse of panic disorder; treatment of social anxiety disorder/ social phobia; treatment of generalised anxiety disorder; and treatment of post-traumatic stress disorder

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - moxonidine, quantity: 200 microgram - tablet, film coated - excipient ingredients: magnesium stearate; lactose monohydrate; crospovidone; povidone; titanium dioxide; hypromellose; iron oxide yellow; macrogol 6000; iron oxide red; macrogol 400 - apo-moxonidine (moxonidine tablets) is indicated for the treatment of hypertension.

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - moxonidine, quantity: 400 microgram - tablet, film coated - excipient ingredients: lactose monohydrate; povidone; magnesium stearate; crospovidone; titanium dioxide; hypromellose; iron oxide yellow; macrogol 6000; iron oxide red; macrogol 400 - apo-moxonidine (moxonidine tablets) is indicated for the treatment of hypertension.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - paroxetine hydrochloride, quantity: 22.22 mg (equivalent: paroxetine, qty 20 mg) - tablet, film coated - excipient ingredients: sodium starch glycollate; magnesium stearate; microcrystalline cellulose; mannitol; basic butylated methacrylate copolymer; titanium dioxide; purified talc; polyvinyl alcohol; sodium lauryl sulfate; glyceryl monostearate - treatment of major depression and for the prevention of relapse of depressive symptoms; treatment of obsessive compulsive disorder and for the prevention of relapse of ocd; treatment of panic disorder and for the prevention of relapse of panic disorder; treatment of social anxiety disorder/ social phobia; treatment of generalised anxiety disorder; and treatment of post-traumatic stress disorder

South Africa - English - South African Health Products Regulatory Authority (SAHPRA)

astral pharma (pty) ltd - tablet - see ingredients - each tablet c ontains caffeine 32 mg codeine phosphate 8 mg meprobamate 150 mg paracetamol 320 mg

Australia - English - Department of Health (Therapeutic Goods Administration)

bristol-myers squibb australia pty ltd - cobicistat, quantity: 150 mg; atazanavir, quantity: 300 mg - tablet, film coated - excipient ingredients: stearic acid; croscarmellose sodium; hyprolose; crospovidone; magnesium stearate; sodium starch glycollate; microcrystalline cellulose; titanium dioxide; hypromellose; purified talc; triacetin; iron oxide red - evotaz is indicated in combination with other antiretroviral agents for the treatment of hiv-1 infection in adults.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - propantheline bromide, quantity: 15 mg - tablet, film coated - excipient ingredients: maize starch; lactose monohydrate; magnesium stearate; purified talc; titanium dioxide; sunset yellow fcf aluminium lake; iron oxide yellow; polyvinyl alcohol; macrogol 3350; lecithin; indigo carmine aluminium lake - this product accepted for registration as 'currently supplied' at the time of commencement of the act. indications were approved as specified in the letter of 7 april 1993 from dr l. hunt are as follows: as an adjunctive therapy in the treatment of peptic ulcer (gastric and duodenal), neurogenic bladder, urinary incontinence in patients with detrusor hyperactivity and hyperhidrosis.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - oxycodone hydrochloride, quantity: 20 mg - tablet, modified release - excipient ingredients: hypromellose; copovidone; microcrystalline cellulose; medium chain triglycerides; titanium dioxide; magnesium stearate; maize starch; stearic acid; lactose monohydrate; colloidal anhydrous silica; behenoyl polyoxyglycerides; hydrogenated castor oil; iron oxide red - oxycodone sandoz modified release tablet is indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive; and ? requires daily, continuous, long term treatment. oxycodone sandoz modified release tablet is not indicated for use in chronic non-cancer pain other than in exceptional circumstances. oxycodone sandoz modified release tablet is not indicated as an as-needed (prn) analgesia.